Skip to main content
OpenTrials
Completed

NCT Number: NCT04784325

Anti-Mullerian Hormone - At My Home

The AMH^2 (Anti-Mullerian Hormone - At My Home) study is a head-to-head-to-head validation study aiming to evaluate the concordance of AMH levels found in blood collected via three different routes: collected at-home using the TAP II device, drawn through standard venipuncture techniques, and collected with the ADx card, another at-home collection device widely available on the market for commercial use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Turtle Health Pop-up Clinic

Brookline, Massachusetts, 02445, United States

About this study

Today, information regarding fertility potential is challenging to obtain for healthy women; clinically meaningful in-clinic testing is limited by physician availability and patient willingness to undergo testing in-clinic. Meanwhile, at-home hormonal bloodwork relies on the use of an ADx card, and is not widely accepted as clinically reliable by the medical community. The Sponsor is developing a comprehensive home fertility assessment to enable couples to proactively estimate and manage their fertility and family building options. Accurate and reliable at-home AMH testing is necessary to reach this goal.

This study aims to validate the clinical excellence and medical accuracy of blood drawn via the TAP II device relative to a standard in-clinic venipuncture draw and other options available on the market to support emerging telemedicine care models. In doing so, the Sponsor may receive CLIA validation for the TAP II in AMH testing and commercialize a Lab Developed Test.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Study Participants

Inclusion criteria

  • Women between the ages of 20 and 39, inclusive (two age brackets above)
  • Women able to freely give consent electronically, given COVID. For the purposes of this study, this is defined as women who speak native or fluent English; and have a high school degree or equivalent, and who are otherwise, in the professional judgement of the PI, able to give informed consent
  • Women who are in driving distance from Boston

Exclusion criteria

  • Turtle Health employees
  • Women who do not speak English natively or fluently
  • Women who have recently given birth, and have had fewer than 3 postpartum menstrual cycles
  • Women who have recently had a stillbirth or abortion more than 20 weeks (subject to the 3 postpartum menstrual cycles above). Miscarriages or abortions less than 20 weeks are subject to wait 2 cycles
  • Women who are currently pregnant or may be pregnant
  • Women who have known blood hypo- or hypercoagulability disorders or known blood clotting issues
  • Any woman the PI believes is not capable of giving independent, informed consent

Treatment and study plan

Blood draw through TAP II

Diagnostic Test

Two self-administered blood draws through TAP II device

Blood draw through ADx cardT

Diagnostic Test

One self-administered ADx card blood draw

Blood draw through standard venipuncture

Diagnostic Test

One phlebotomist-performed standard venipuncture

Primary outcomes

  1. Correlation (r-squared) of the AMH levels resulting from the shipped TAP II samples and venipuncture samples.

    Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery

    Evaluate the concordance of the TAP blood collection device after shipment with in-clinic blood collection for AMH.

Secondary outcomes

  1. Correlation (r-squared) of AMH levels from stored TAP II samples and venipuncture samples

    Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery

    Evaluate the concordance of the TAP blood collection device without shipment with in-clinic blood collection for AMH for control versus venipuncture "ground truth".

  2. Correlation (r-squared) of AMH levels from stored ADx samples and venipuncture samples.

    Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery

    Evaluate the concordance of the ADx card comparator device with in-clinic blood collection for AMH for control versus venipuncture "ground truth".

  3. Number of women changing risk bands

    Time frame: Lab analysis 72 hours after ADx card/venipuncture/TAP II hand delivery

    The number of participants who move to a different risk strata for their age and hormonal birth control status. This will be defined by changing to a different row for their AMH concentration range, treating venipuncture as the "Gold Standard" and comparing the number of women who move rows utilizing their TAP draws or ADx card draw.

  4. NPS superiority

    Time frame: Survey collected within 3 days of blood draw

    Superiority of net promoter score of TAP II device compared to venipuncture as measured by a post-draw survey (calculated as a standard NPS: 9/10 scores - 0-6 scores).

  5. Self-reported pain

    Time frame: Survey collected within 3 days of blood draw

    Self-reported pain of different draw methods as measured by a post-draw using the Stanford Pain Scale.

Sponsors and collaborators

Lead sponsor

Turtle Health, Inc.

Industry

Registry information

Official study title

AMH^2: Anti-Müllerian Hormone - At My Home

Acronym: AMH^2

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 5, 2021
Registry last updated
Jun 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.